Research
DNSP-11 — living evidence map
The Atlas page holds the claims; this is how its evidence evolved.
Summary
DNSP-11 (dopamine neuron stimulating peptide-11) is an 11-amino-acid amidated peptide proposed to arise from the proregion of the human GDNF precursor; a single dose into the rat substantia nigra increased potassium-evoked dopamine release in parts of the striatum two weeks later. · pmid:24406899
Given intranasally for three weeks to rats, DNSP-11 increased dopamine turnover and, in a 6-hydroxydopamine model of Parkinson's disease, reduced amphetamine-induced rotation and spared some dopamine neurons. · pmid:25999268
Identity
No public registry record is shown for this page: PubChem gave no record that proves it is this substance.
Where the evidence actually sits
Proportion of the 2 claims about DNSP-11 standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for DNSP-11 yet.
Dose evidence, rung by rung
No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.
- Approved-label dose · a resolved regulatory document names a labelled dose
nothing resolved on this rung
- Studied human doses · resolved human studies at the established tier
nothing resolved on this rung
- Observational evidence · resolved human data at the emerging tier: thin, or contested
nothing resolved on this rung
- Community-reported protocols · protocol propositions from distinct members, counted once per human
nothing resolved on this rung
- Preclinical evidence · resolved animal, cell or mechanistic work
- Dynamic changes in dopamine neuron function after DNSP-11 treatment: effects in vivo and increased ERK 1/2 phosphorylation in vitro. · pmid 24406899 · 2014
- Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease. · pmid 25999268 · 2015
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.